La bourse ferme dans 2 h 45 min

The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025

ReportLinker FR

Antibiotics Market by Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

New York, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antibiotics Market by Class, Drug Origin, Spectrum of Activity, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018 - 2025" - https://www.reportlinker.com/p05663917/?utm_source=GNW

Antibiotics Market Overview :

The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025.

Antibiotic is an antimicrobial substance, which are used in the treatment and prevention of bacterial infections, as well as used rarely to combat protozoan infections. Antibiotics are the medicines that either discontinue bacteria from growing or destroy bacteria straight referred as bacteriostatic and bactericidal antibiotics respectively. Easy accessibility of antibiotics at drug stores and in hospitals with prescription or without prescription fuels their consumption across the world. Moreover, increases antibiotics demand during transplants, dialysis, suppressed immune system, joint replacement, and others boosts the market growth.

Surge in demand for antibiotics, owing to increased consumption in low- & middle-income countries and rise in prevalence of infectious diseases are the key factors that boost the growth of the global antibiotics market. In addition, development of novel approaches for new antibiotics to treat bacterial infections and increase in clinical trials to determine safety & efficacy of the antibiotics drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for regulatory approval are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer lucrative opportunities for the market players.

The global antibiotics market is segmented based on class, drug origin, spectrum of activity, route of administration, and region. On the basis of class, the market is classified as beta lactam & beta lactamase inhibitors, macrolides, quinolones, and others. The beta lactam & beta lactamase inhibitors segment is further segmented into penicillin, cephalosporin, monobactam, and carbapenem. Depending on drug origin, the antibiotics market is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. Based on route of administration, it is segregated into oral, intravenous, and others. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Antibiotics Market :

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.

An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.

A comprehensive analysis of the factors that drive and restrain the growth of the global antibiotics market is provided.

An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

Antibiotics Key Market Segments :

By Class

Beta Lactam & Beta Lactamase Inhibitors

Penicillin

Cephalosporin

Carbapenem

Monobactam

Quinolones

Macrolides

Others

By Drug Origin

Natural

Semisynthetic

Synthetic

By Spectrum of Activity

Broad-spectrum Antibiotic

Narrow-spectrum Antibiotic

By Route of Administration

Oral

Intravenous

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

Spain

Italy

UK

Rest of Europe

Asia-Pacific

Australia

Japan

India

China

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

KEY MARKET PLAYERS

Abbott Laboratories

Allergan Plc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc.

Merck & Co. Inc.

Mylan N.V.

Novartis International AG (Sandoz)

Pfizer Inc.

Sanofi

Teva Pharmaceutical Industries Ltd.

The other players in the value chain include (profiles not included in the report):
Aurobindo Pharma

Bayer HealthCare

Eli Lilly

Lupin Pharmaceuticals

Sun Pharmaceutical

Shionogi
Read the full report: https://www.reportlinker.com/p05663917/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001